GILEAD SCIENCES, INC. (GILD)
Biological Products, (No Diagnostic Substances)
Latest Price
$130.21
TTM P/E
17.72
Normalized P/E
32.11
Div Yield
2.45%
Book Value
18.93
P/B Ratio
6.88
Valuation metrics
adjust assumptions →EPS: $6.78
Book value / share: $18.29
Formula: √(22.5 × EPS × BVPS)
Graham Number
$52.83
59% downside
Norm. op. income: $7.3B (median of 7yr)
Tax rate: 21%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$30.18
77% downside
Base FCF: $9.5B (median of recent 5yr)
Growth: -9%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$31.86
76% downside
EPS: $6.78
Target P/E: 32×
Formula: EPS × P/E
P/E Fair Value
$216.96
+67% upside
Institutional Ownership
81.2% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 119.01M | $16.59B | 9.58% | -4.18M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 80.65M | $11.24B | 6.49% | -- | 2026-03-31 |
| FMR LLC | 71.91M | $10.02B | 5.79% | +6.33M | 2026-03-31 |
| STATE STREET CORP | 59.86M | $8.34B | 4.82% | -381.9K | 2026-03-31 |
| Capital World Investors | 41.28M | $5.75B | 3.32% | -1.59M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 35.13M | $4.89B | 2.83% | -- | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 29.73M | $4.13B | 2.39% | +30.1K | 2026-03-31 |
| Capital Research Global Investors | 27.13M | $3.78B | 2.18% | +1.82M | 2026-03-31 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 26.25M | $3.66B | 2.11% | -1.45M | 2026-03-31 |
| Dodge & Cox | 24.25M | $3.38B | 1.95% | -2.03M | 2026-03-31 |